Corbus Pharmaceuticals Holdings, Inc. (CRBP)
| Market Cap | 174.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -78.54M |
| Shares Out | 17.74M |
| EPS (ttm) | -5.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 207,566 |
| Open | 10.04 |
| Previous Close | 10.08 |
| Day's Range | 9.70 - 10.29 |
| 52-Week Range | 6.10 - 20.56 |
| Beta | 2.79 |
| Analysts | Strong Buy |
| Price Target | 45.60 (+364.36%) |
| Earnings Date | May 8, 2026 |
About CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CRBP stock is "Strong Buy." The 12-month stock price target is $45.6, which is an increase of 364.36% from the latest price.
News
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares are down on Tuesday as the company announced broad alignment with the FDA regarding the registration path for its CRB-701 treatment.
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage company focused on promising new therapies in onco...
Corbus Pharmaceuticals Holdings Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Two lead clinical programs are advancing: CRB-701, a differentiated Nectin-4 ADC targeting underserved oncology indications, and CRB-913, a novel peripherally restricted CB1 inverse agonist for obesity, both with transformative data expected in 2024. CRB-701 shows strong safety and efficacy signals, while CRB-913 demonstrates rapid, significant weight loss with minimal neuropsychiatric risk.
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D....
Corbus Pharmaceuticals Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
CRB-701 is advancing in head and neck and cervical cancer with key data and regulatory updates expected this year. CRB-913 shows strong early weight loss efficacy and safety, with no neuropsychiatric events, and a pivotal phase 1B study is planned. Cash reserves support operations into 2028.
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D....
Corbus Pharmaceuticals Holdings Transcript: Study Update
CRB-913 showed strong safety and tolerability in a phase I SAD-MAD study, with minimal GI and neuropsychiatric adverse events and early, significant weight loss in participants with obesity. The drug’s peripherally restricted mechanism led to weight loss not driven by GI side effects, supporting its differentiated profile and potential for combination therapy.
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the s...
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
Company will host conference call and live webcast to review and discuss the data at 8:00 am ET Company will host conference call and live webcast to review and discuss the data at 8:00 am ET
Corbus Pharmaceuticals Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference
Key data from oncology and obesity programs are expected over the next 12-18 months, with a focus on differentiated safety and efficacy profiles. Strategic priorities include advancing pivotal studies in head and neck and cervical cancer, and progressing the CB1 obesity program, supported by a strong cash position.
Corbus Pharmaceuticals Holdings Transcript: Jefferies London Healthcare Conference 2025
The company highlighted strong efficacy and manageable safety for its Nectin-4 ADC in head and neck and cervical cancers, with key durability data expected mid-next year. Its obesity program will deliver phase 1B data in 2024, and a robust cash position supports multiple upcoming catalysts.
Corbus Pharmaceuticals Holdings Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Three key assets are advancing: CRB-701 (Nectin-4 ADC) shows promising efficacy and safety in head and neck cancer, with a pivotal study planned for mid-next year. CRB-913 (obesity) and CRB-601 (solid tumors) are progressing, with major data readouts expected in 2024.
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced it will be particip...
Corbus Pharmaceuticals Announces Pricing of Public Offering
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an u...
Corbus Pharmaceuticals Announces Proposed Public Offering
NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to of...
Corbus Pharmaceuticals Holdings Transcript: KOL Event
CRB-701 shows encouraging efficacy and a differentiated safety profile in advanced head and neck cancer, with broad patient eligibility and rapid trial enrollment. Durable responses and manageable toxicities position it well for further development in later-line settings.
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company') today announced data from its Phase 1/2 clinical study of CRB-701 (SY...
FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, announced today that...
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today anno...
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of ...
Corbus Pharmaceuticals Holdings Transcript: Jefferies Global Healthcare Conference 2025
Three clinical assets are advancing, with key oncology and obesity data expected in the second half of the year. The company is leveraging strong international partnerships, focusing on safety and efficacy benchmarks, and is well-funded through mid-2027.
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of C...
Corbus Pharmaceuticals Holdings Transcript: RBC Capital Markets Global Healthcare Conference 2025
Western data for CRB-701 show a safer profile and promising efficacy, with head and neck and cervical cancers prioritized for expansion. CB1 inverse agonist 913 and alpha V beta 8 antibody 601 are advancing, with all major readouts expected in the second half of the year.
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rache...
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, annou...